Back to first-pass browser

First-pass extracted concept

DNA-PK inhibitors

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

DNA-PK inhibitors impede recruitment of the repair complex needed for successful DSB repair in NHEJ. The abstract frames them as agents that sensitize tumor cells to radiation and DNA-damaging chemotherapy.

Source 1DOIPubMed

What problem it solves

They are proposed to overcome intrinsic radioresistance by blocking the primary rapid-response pathway for radiation-induced double-strand break repair.

Source 1DOIPubMed

What it does not solve

The abstract states unresolved issues around tumor subtype selection, sparing normal tissues, and translating preclinical findings into clinical benefit.

Source 1DOIPubMed

Alternatives

The abstract contrasts NHEJ with homologous recombination as a different DSB repair pathway, but does not present a direct alternative therapeutic tool.

Source 1DOIPubMed

Evidence Snippets

Consequently, inhibitors of DNA-PK have emerged as promising therapeutic agents to sensitize tumor cells to radiation and DNA-damaging chemotherapeutics.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1mechanismsupports2026Source 1DOIPubMed

Inhibiting DNA-PK-mediated recruitment of the repair complex needed for successful DSB repair promotes cell death through apoptosis or mitotic catastrophe.

Quoted textsource-backed
Inhibiting the DNA-PK ability to recruit the protein complex needed for successful DSB repair promotes cell death through apoptosis or mitotic catastrophe.
Claim 2therapeutic rationalesupports2026Source 1DOIPubMed

DNA-PK inhibitors are promising therapeutic agents for sensitizing tumor cells to radiation and DNA-damaging chemotherapeutics.

Quoted textsource-backed
Consequently, inhibitors of DNA-PK have emerged as promising therapeutic agents to sensitize tumor cells to radiation and DNA-damaging chemotherapeutics.
Claim 3therapeutic strategysupports2026Source 1DOIPubMed

Implementation of DNA-PK inhibitors in medical practice could stratify patients based on tumor vulnerability to NHEJ disruption and support combination with radiation or DNA-damaging chemotherapy.

Quoted textsource-backed
The implementation of DNA-PK inhibitors into medical practice can enable the stratification of oncologic patients into two categories, based on the tumors' vulnerability to NHEJ disruptions. Thus, the therapeutic pathways of patients with NHEJ tumors could branch, combining traditional genotoxic therapies (radiation and DNA-damaging chemotherapeutics) with DNA-PK inhibitors to achieve an enhanced effect and improved survival outcomes.